Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura

Dow Jones03-17 07:12

By Katherine Hamilton

Lensar and Alcon agreed to terminate their merger agreement. Lensar's stock sank 23%, to $7.89, in after-hours trading Monday.

Rhythm Pharmaceuticals said its obesity treatment didn't meet primary endpoints in a recent trial. Shares shed 6%, to $85, after the bell.

TruBridge said it would delay its fourth-quarter earnings report after finding errors in previous financial statements. The stock fell 6% to $16.55.

Kaltura plans to acquire PathFactor for $22 million to expand its AI capabilities. Shares gained 8%, to $1.50.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 16, 2026 19:12 ET (23:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620902524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 07:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620902524","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Lensar and Alcon agreed to terminate their merger agreement. Lensar's stock sank 23%, to $7.89, in after-hours trading Monday. \n</p>\n<p>\n  Rhythm Pharmaceuticals said its obesity treatment didn't meet primary endpoints in a recent trial. Shares shed 6%, to $85, after the bell. \n</p>\n<p>\n  TruBridge said it would delay its fourth-quarter earnings report after finding errors in previous financial statements. The stock fell 6% to $16.55. \n</p>\n<p>\n  Kaltura plans to acquire PathFactor for $22 million to expand its AI capabilities. Shares gained 8%, to $1.50. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 19:12 ET (23:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-17 07:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Lensar and Alcon agreed to terminate their merger agreement. Lensar's stock sank 23%, to $7.89, in after-hours trading Monday. \n</p>\n<p>\n  Rhythm Pharmaceuticals said its obesity treatment didn't meet primary endpoints in a recent trial. Shares shed 6%, to $85, after the bell. \n</p>\n<p>\n  TruBridge said it would delay its fourth-quarter earnings report after finding errors in previous financial statements. The stock fell 6% to $16.55. \n</p>\n<p>\n  Kaltura plans to acquire PathFactor for $22 million to expand its AI capabilities. Shares gained 8%, to $1.50. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 19:12 ET (23:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620902524","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620902524","pubTimestamp":1773702720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lensar and Alcon agreed to terminate their merger agreement. Lensar's stock sank 23%, to $7.89, in after-hours trading Monday.Rhythm Pharmaceuticals said its obesity treatment didn't meet primary endpoints in a recent trial. Shares shed 6%, to $85, after the bell.TruBridge said it would delay its fourth-quarter earnings report after finding errors in previous financial statements. The stock fell 6% to $16.55.Kaltura plans to acquire PathFactor for $22 million to expand its AI capabilities. Shares gained 8%, to $1.50.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","BK4082":"医疗保健设备","RYTM":"Rhythm Pharmaceuticals Inc.","BK4167":"医疗保健技术","BK4139":"生物科技","LNSR":"LENSAR Inc","TBRG":"TRUBRIDGE INC","BK4539":"次新股","KLTR":"Kaltura, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"值得关注的股票：Lensar、Rhythm Pharmaceuticals、TruBridge、Kaltura","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":0.9,"TBRG":0.9,"KLTR":1.5,"LNSR":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Lensar and Alcon agreed to terminate their merger agreement. Lensar's stock sank 23%, to $7.89, in after-hours trading Monday. \n\n\n  Rhythm Pharmaceuticals said its obesity treatment didn't meet primary endpoints in a recent trial. Shares shed 6%, to $85, after the bell. \n\n\n  TruBridge said it would delay its fourth-quarter earnings report after finding errors in previous financial statements. The stock fell 6% to $16.55. \n\n\n  Kaltura plans to acquire PathFactor for $22 million to expand its AI capabilities. Shares gained 8%, to $1.50. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 19:12 ET (23:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620902524","isCrawlerRequest":true}